AstraZeneca's Alexion completes acquisition of genomic medicine company LogicBio
Roland Magnusson/iStock Editorial via Getty Images                 

AstraZeneca's (NASDAQ:AZN) rare diseaseÂ unit Alexion completed the acquisition of genomic medicine companyÂ LogicBio TherapeuticsÂ (NASDAQ:LOGC).
Frederic Chereau, CEO of LogicBio, will join Alexion as senior vice president, Strategy and Business Development.
The tender offer ofÂ $2.07 per share expired on Nov. 15.
LogicBio's common stock ceased trading on Nasdaq. Alexion will retain LogicBio employees at their current location, the British pharma giant said in a press release on Wednesday.